Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2021 | $4.00 | Buy | HC Wainwright & Co. |
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
SOLANA BEACH, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that on May 20, 2025 Artelo's Board of Directors approved a 6-for-1 reverse stock split ("Reverse Split") of the Company's common stock ("Common Stock"). The Company's common shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open, June 13, 2025. The Board of Directors determined the 6-for-1 ratio to be appropriate in order to increase the
SOLANA BEACH, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced its presentation of new data at the British Pain Conference held in Newport, Wales, UK on June 3-5, 2025 (https://bpsasm.org/) that further validates the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating osteoarthritis (OA) pain. Professor Saoirse O'Sullivan, Vice President of Translation Sciences at Artelo Biosciences, presented results from an animal study tit
SOLANA BEACH, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today welcomed the publication of a comprehensive review in Neurobiology of Disease, titled "Fatty acid binding proteins and their involvement in anxiety and mood disorders," that underscores the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating mood and anxiety disorders. The peer-reviewed article was co-authored by Doctor Steven Laviolette, Professor in the Schulich School of
HC Wainwright & Co. initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $4.00
LADENBURG THALM/SH SH initiated coverage of Artelo Biosciences with a rating of Buy
Ladenburg Thalmann initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $7.00
8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
10-Q - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)